Back to News
Market Impact: 0.4
Immunome's IM-1340 Receives FDA IND Clearance For Advanced Solid Tumors
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Immunome received FDA clearance for the IND application for IM-1340, a potential first-in-class antibody-drug conjugate targeting oncology indications. The clearance enables the clinical-stage company to advance IM-1340 into human clinical development, representing a positive pipeline and regulatory milestone.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
IMNM0.82
More News
- California Gov. Gavin Newsom bans AI 'robo bosses' in landmark state law, reversing his earlier veto
- US judge approves settlement allowing Paramount to acquire Warner Bros
- Why is Nidec stock plunging today?
- Google rolls out Gemini 4 Argon, its most advanced AI model
- Huawei unveils Mate 90 phones, leans on homegrown chip design to offset US curbs
- Meta stock enjoys best month since 2022 on AI momentum